RxDoctor Payments Data

Rebecca Novacek, MD

Neurology · Grand Forks, NDNPI 1861628711

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $404 of the $554 with a category attached, or 72.9%. 9 manufacturers reported payments, led by Biogen at 27.1% of the total. Reporting peaked in 2024 at $308 and has fallen 51.3% since, to $150 in 2025.

$554in general payments, 2019–2025

Across 12 payments — averaging $46.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$150
  • AstraZeneca$121
  • Eisai Inc.$81
  • UCB, Inc.$70
  • SK Life Science, Inc.$50
  • AbbVie$34
  • plus $48 from 3 others

What the payments were for

  • Consulting fees$15027%
  • Food & beverage$40473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$554 in reported general payments places this provider in the 55th percentile of 39 neurology providers in North Dakota.

See all neurology providers in North Dakota

Medicare billing

Part B allowed, 2024
$112,039
Medicare patients
451
Services billed
2,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate48$59,212
UbrelvyUbrogepant23$21,964
Aimovig AutoinjectorErenumab-Aooe21$15,565
Carbidopa-LevodopaCarbidopa/Levodopa373$14,493
Emgality PenGalcanezumab-Gnlm19$13,855
Tetrabenazine12$12,864
Emgality SyringeGalcanezumab-Gnlm14$9,144
FingolimodFingolimod Hcl11$7,140
Levetiracetam210$6,061
Felbamate14$5,193
Primidone103$2,975
Lamotrigine118$2,570
RivastigmineRivastigmine Tartrate33$2,170
Oxcarbazepine47$2,065
Propranolol Hcl14$2,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$34$21,96423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 39 neurology providers in North Dakota.

Other neurology in Grand Forks

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →